Federated Hermes Inc. Decreases Stock Holdings in Pediatrix Medical Group, Inc. (NYSE:MD)

Federated Hermes Inc. lessened its position in shares of Pediatrix Medical Group, Inc. (NYSE:MD) by 28.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 162,532 shares of the company’s stock after selling 64,702 shares during the quarter. Federated Hermes Inc. owned about 0.19% of Pediatrix Medical Group worth $1,227,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. American Century Companies Inc. grew its stake in Pediatrix Medical Group by 13.7% during the 2nd quarter. American Century Companies Inc. now owns 124,395 shares of the company’s stock worth $939,000 after buying an additional 15,023 shares during the last quarter. ClariVest Asset Management LLC purchased a new stake in shares of Pediatrix Medical Group during the second quarter worth about $1,721,000. Texas Permanent School Fund Corp increased its holdings in shares of Pediatrix Medical Group by 29.6% during the second quarter. Texas Permanent School Fund Corp now owns 93,367 shares of the company’s stock valued at $705,000 after acquiring an additional 21,351 shares in the last quarter. Ballentine Partners LLC purchased a new position in shares of Pediatrix Medical Group in the 2nd quarter valued at approximately $132,000. Finally, nVerses Capital LLC acquired a new stake in Pediatrix Medical Group in the 2nd quarter worth approximately $31,000. Institutional investors own 97.71% of the company’s stock.

Pediatrix Medical Group Stock Down 2.9 %

Shares of MD opened at $10.56 on Friday. The company has a market capitalization of $888.59 million, a price-to-earnings ratio of -12.42, a PEG ratio of 1.68 and a beta of 1.56. Pediatrix Medical Group, Inc. has a 52 week low of $6.62 and a 52 week high of $13.01. The stock’s 50-day moving average price is $9.71 and its 200-day moving average price is $8.82. The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 0.87.

Pediatrix Medical Group (NYSE:MD) last released its quarterly earnings data on Tuesday, August 6th. The company reported $0.34 EPS for the quarter, topping the consensus estimate of $0.31 by $0.03. The business had revenue of $504.30 million for the quarter, compared to analyst estimates of $505.49 million. Pediatrix Medical Group had a positive return on equity of 10.59% and a negative net margin of 12.58%. During the same quarter in the prior year, the firm posted $0.37 EPS. The business’s quarterly revenue was up .7% compared to the same quarter last year. On average, sell-side analysts predict that Pediatrix Medical Group, Inc. will post 1.18 EPS for the current year.

Insider Buying and Selling at Pediatrix Medical Group

In other news, Director Laura A. Linynsky sold 7,000 shares of the stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $11.16, for a total transaction of $78,120.00. Following the sale, the director now directly owns 30,805 shares of the company’s stock, valued at approximately $343,783.80. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other Pediatrix Medical Group news, CFO C Marc Richards sold 17,438 shares of the company’s stock in a transaction on Monday, August 12th. The shares were sold at an average price of $10.08, for a total transaction of $175,775.04. Following the completion of the transaction, the chief financial officer now directly owns 175,347 shares in the company, valued at $1,767,497.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Laura A. Linynsky sold 7,000 shares of Pediatrix Medical Group stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $11.16, for a total transaction of $78,120.00. Following the completion of the sale, the director now owns 30,805 shares in the company, valued at approximately $343,783.80. The disclosure for this sale can be found here. Over the last quarter, insiders sold 68,100 shares of company stock valued at $701,889. Corporate insiders own 2.00% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on MD shares. Truist Financial upped their price target on shares of Pediatrix Medical Group from $8.00 to $10.00 and gave the company a “hold” rating in a research note on Thursday, August 15th. Deutsche Bank Aktiengesellschaft raised Pediatrix Medical Group from a “sell” rating to a “hold” rating and set a $8.00 price target for the company in a research report on Friday, June 7th. StockNews.com raised Pediatrix Medical Group from a “sell” rating to a “hold” rating in a report on Wednesday, August 7th. Finally, UBS Group lifted their target price on Pediatrix Medical Group from $9.00 to $10.50 and gave the stock a “neutral” rating in a report on Friday, August 9th. Six research analysts have rated the stock with a hold rating, According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $9.30.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.